title: Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation.
abstract: Raltegravir is a novel HIV-1 integrase inhibitor with potent in vitro activity (95% inhibitory concentration = 33 nM in 50% human serum). In vitro characterization of raltegravir inhibition potential was assessed against a panel of cytochrome P450 (CYP) enzymes. An open-label, 2-period study was conducted to assess the effect of raltegravir on the pharmacokinetics of midazolam, a sensitive CYP 3A4 probe substrate: period 1, 2.0 mg of midazolam; period 2, 400 mg of raltegravir every 12 hours for 14 days with 2.0 mg of midazolam on day 14. There was no meaningful in vitro effect of raltegravir on inhibition of a panel of CYP enzymes and induction of CYP 3A4. In the presence of raltegravir, midazolam area under the curve extrapolated to infinity (AUC(0-infinity)) and maximum plasma concentration (C(max)) geometric mean ratios were similar (geometric mean ratios and 90% confidence intervals: 0.92 [0.82, 1.03] (P = .208) and 1.03 [0.87, 1.22] (P = .751), respectively). No substantial differences were observed in T(max) (P = .750) or apparent half-life (P = .533) of midazolam. Plasma levels of midazolam were not substantially affected by raltegravir, which implies that raltegravir is not a clinically important inducer or inhibitor of CYP 3A4 and that raltegravir would not be expected to affect the pharmacokinetics of other drugs metabolized by CYP 3A4 to a clinically meaningful extent.
authors: Merck & Co, Inc, Whitehouse Station, NJ, USA.
authors: Marian
authors: M
authors: Iwamoto
authors: Kelem
authors: K
authors: Kassahun
authors: Matthew D
authors: MD
authors: Troyer
authors: William D
authors: WD
authors: Hanley
authors: Ping
authors: P
authors: Lu
authors: Alisha
authors: A
authors: Rhoton
authors: Amelia S
authors: AS
authors: Petry
authors: Kalyan
authors: K
authors: Ghosh
authors: Eric
authors: E
authors: Mangin
authors: Emanuel P
authors: EP
authors: DeNoia
authors: Larissa A
authors: LA
authors: Wenning
authors: Julie A
authors: JA
authors: Stone
authors: Keith M
authors: KM
authors: Gottesdiener
authors: John A
authors: JA
authors: Wagner
mesh_terms: D019540:Area Under Curve; D002478:Cells, Cultured; D002853:Chromatography, Liquid; D018592:Cross-Over Studies; D051544:Cytochrome P-450 CYP3A / Q000235:genetics / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D019428:HIV Integrase Inhibitors / Q000494:pharmacology; D006207:Half-Life; D022781:Hepatocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D008297:Male; D013058:Mass Spectrometry; D008657:Metabolic Clearance Rate; D008862:Microsomes, Liver / Q000187:drug effects / Q000378:metabolism; D008874:Midazolam / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D009930:Organic Chemicals / Q000494:pharmacology*; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D019428:HIV Integrase Inhibitors; D009930:Organic Chemicals; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D008874:Midazolam